BACKGROUND: The differential diagnosis for hereditary ataxia encompasses a variety of diseases characterized by both autosomal dominant and recessive inheritance. There are no curative treatments available for these neurodegenerative conditions. This open label treatment study used human umbilical cord blood-derived mononuclear cells (CBMC) combined with rehabilitation training as potential disease modulators. METHODS: 30 patients suffering from hereditary ataxia were treated with CBMCs administered systemically by intravenous infusion and intrathecally by either cervical or lumbar puncture. Primary endpoint measures were the Berg Balance Scale (BBS), serum markers of immunoglobulin and T-cell subsets, measured at baseline and pre-determined times post-treatment. RESULTS: A reduction of pathological symptoms and signs was shown following treatment. The BBS scores, IgG, IgA, total T cells and CD3+CD4 T cells all improved significantly compared to pre-treatment values (P < 0.01~0.001). There were no adverse events. CONCLUSION: The combination of CBMC infusion and rehabilitation training may be a safe and effective treatment for ataxia, which dramatically improves patients' functional symptoms. These data support expanded double blind, placebo-controlled studies for these treatment modalities.
BACKGROUND: The differential diagnosis for hereditary ataxia encompasses a variety of diseases characterized by both autosomal dominant and recessive inheritance. There are no curative treatments available for these neurodegenerative conditions. This open label treatment study used human umbilical cord blood-derived mononuclear cells (CBMC) combined with rehabilitation training as potential disease modulators. METHODS: 30 patients suffering from hereditary ataxia were treated with CBMCs administered systemically by intravenous infusion and intrathecally by either cervical or lumbar puncture. Primary endpoint measures were the Berg Balance Scale (BBS), serum markers of immunoglobulin and T-cell subsets, measured at baseline and pre-determined times post-treatment. RESULTS: A reduction of pathological symptoms and signs was shown following treatment. The BBS scores, IgG, IgA, total T cells and CD3+CD4 T cells all improved significantly compared to pre-treatment values (P < 0.01~0.001). There were no adverse events. CONCLUSION: The combination of CBMC infusion and rehabilitation training may be a safe and effective treatment for ataxia, which dramatically improves patients' functional symptoms. These data support expanded double blind, placebo-controlled studies for these treatment modalities.
Authors: F Locatelli; A Bersano; E Ballabio; S Lanfranconi; D Papadimitriou; S Strazzer; N Bresolin; G P Comi; S Corti Journal: Cell Mol Life Sci Date: 2009-03 Impact factor: 9.261
Authors: Svitlana Garbuzova-Davis; Alison E Willing; Tanja Zigova; Samuel Saporta; Eleanor B Justen; Jennifer C Lane; Jennifer E Hudson; Ning Chen; Cyndy D Davis; Paul R Sanberg Journal: J Hematother Stem Cell Res Date: 2003-06
Authors: M Jawad Javed; Laura E Mead; Daniel Prater; Waylan K Bessler; David Foster; Jamie Case; W Scott Goebel; Mervin C Yoder; Laura S Haneline; David A Ingram Journal: Pediatr Res Date: 2008-07 Impact factor: 3.756
Authors: D Eugene Redmond; Kimberly B Bjugstad; Yang D Teng; Vaclav Ourednik; Jitka Ourednik; Dustin R Wakeman; Xuejun H Parsons; Rodolfo Gonzalez; Barbara C Blanchard; Seung U Kim; Zezong Gu; Stuart A Lipton; Eleni A Markakis; Robert H Roth; John D Elsworth; John R Sladek; Richard L Sidman; Evan Y Snyder Journal: Proc Natl Acad Sci U S A Date: 2007-06-22 Impact factor: 11.205
Authors: Dong-Hyuk Park; Cesar V Borlongan; Alison E Willing; David J Eve; L Eduardo Cruz; Cyndy D Sanberg; Yong-Gu Chung; Paul R Sanberg Journal: Cell Transplant Date: 2009-04-29 Impact factor: 4.064
Authors: Jun Li; Li Zhang; Liang Zhou; Zheng-Ping Yu; Feng Qi; Bei Liu; Su-Xia Zi; Li Li; Yi Li; San-Bin Wang; Zheng-Jiang Cui; Xing-Hua Pan Journal: J Transl Med Date: 2012-05-21 Impact factor: 5.531
Authors: Jennifer J Carr; Joyce Lalara; Gayangwa Lalara; Moira Smith; Jennifer Quaill; Alan R Clough; Anne Lowell; Ruth N Barker Journal: BMJ Open Date: 2019-09-30 Impact factor: 2.692
Authors: Lucía Calatrava-Ferreras; Rafael Gonzalo-Gobernado; Antonio S Herranz; Diana Reimers; Teresa Montero Vega; Adriano Jiménez-Escrig; Luis Alberto Richart López; Eulalia Bazán Journal: Stem Cells Int Date: 2012-10-24 Impact factor: 5.443
Authors: Neha Karlupia; Nathan C Manley; Kameshwar Prasad; Richard Schäfer; Gary K Steinberg Journal: Stem Cell Res Ther Date: 2014-04-01 Impact factor: 6.832